Skip to main content
Log in

Erysipelas

Recognition and Management

  • Therapy in Practice
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Erysipelas is an acute bacterial infection of the dermis and hypodermis that is associated with clinical inflammation. It is a specific clinical type of cellulitis and, as such, it should be studied as a specific entity. Erysipelas is generally caused by group A streptococci; it is highly probable that streptococcal toxins also play a role, which could, in part, help explain the clinical inflammation.

Erysipelas of the leg is the main clinical type encountered. The face, arm, and upper thigh are the other most common sites for the occurrence of erysipelas. After a sudden onset, areas of erythema and edema characteristically enlarge with well-defined margins. Athlete’s foot is the most common portal of entry for the disease. Erysipelas is generally associated with high fever, and adenopathy and lymphangitis are sometimes present.

At the time of diagnosis, it is important to look for clinical markers of severity (local signs and symptoms, general signs and symptoms, co-morbidity, social context) which would necessitate hospitalization.

There are many differential diagnoses, particularly in the case of atypical dermo-hypodermitis. Some bacterial infections may have specific clinical aspects or may lead to a diagnosis of cellulitis. Necrotizing cellulitis or fasciitis are life-threatening diseases and a rapid diagnosis is important. Other noninfectious types of cellulitis have been reported in many diseases, both localized or generalized.

The biology of typical erysipelas is of little value in diagnosis and a laboratory workup is usually not required. There are few local complications associated with erysipelas; abscess can occur in some patients and septicemia is rare. Recurrence is the more distressing complication.

Treatment of patients with erysipelas has been evaluated in a small number of studies. In most of them, erysipelas has been included in therapeutic studies of ‘severe cutaneous infections’. This is not justified as in fact erysipelas is usually sensitive to penicillin G. Amoxicillin and macrolides are also effective. However, comparative, cost-analysis studies need to be performed to determine the best therapeutic option. Bed rest with the leg elevated is also important. Anticoagulants are indicated in patients at risk of venous thromboembolism. The portal of entry will also require treatment. Long-term antibacterial therapy is required for patients with recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Table II
Fig. 3
Table III
Table IV
Table V
Fig. 4
Table VI

Similar content being viewed by others

References

  1. Dupuy A. Epidémiologie descriptive et connaissance des facteurs de risque de l’érysipèle. Ann Dermatol Venereol 2001; 128: 312–316

    PubMed  CAS  Google Scholar 

  2. Bernard P, Bédane C, Mounier M, et al. Dermohypodermites bactériennes de l’adulte. Incidence et place de l’étiologie streptococcique. Ann Dermatol Venereol 1995; 122: 495–500

    PubMed  CAS  Google Scholar 

  3. Conférence de Consensus. Erysipèle et fasciite nécrosante: prise en charge. Ann Dermatol Venereol 2001; 128: 307–482

    Google Scholar 

  4. Denis F, Martin C, Ploy MC. L’érysipéle: données microbiologiques et pathogéniques. Ann Dermatol Venereol 2001; 128: 317–325

    PubMed  CAS  Google Scholar 

  5. Vaillant L. Critères diagnostiques de l’érysipèle. Ann Dermatol Venereol 2001; 128: 326–333

    PubMed  CAS  Google Scholar 

  6. Leyden JJ. Cellulitis. Arch Dermatol 1989; 125: 823–824

    Article  PubMed  CAS  Google Scholar 

  7. Norrby A, Eriksson B, Norgren M, et al. Virulence properties of erysipelas-associated group A streptococci. Eur J Clin Microbiol Infect Dis 1992; 11: 1136–1143

    Article  PubMed  CAS  Google Scholar 

  8. Schmitt JL. Enquête prospective. Erysipèle et cellulites nécrosantes: quelle prise en charge en milieu hospitalier. Ann Dermatol Venereol 2001; 128: 334–337

    Google Scholar 

  9. Duvanel T, Harms M. Erysipèle et cellulites infectieuses: classification, approche diagnostique, traitement. Rundschau Med 1987; 76: 216–219

    CAS  Google Scholar 

  10. Chartier C, Grosshans E. Erysipelas. Int J Dermatol 1990; 29: 459–467

    Article  PubMed  CAS  Google Scholar 

  11. Dupuy A, Benchiki H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case control study. BMJ 1999; 318: 1591–1594

    Article  PubMed  CAS  Google Scholar 

  12. Hamar H, Sverdrup B, Borglund E, et al. Coagulation and fibrinolytic systems during the course of erysipelas and necrotizing fasciitis and the effect of heparin. Acta Derm Venereol (Stockh) 1985; 65: 495–503

    Google Scholar 

  13. Schultz-Ehrenburg U, Weindorf N, Tourbier H. Das nekrotisierende Erysipel: beziehungen zu angiologischen Grundkrankheiten. Z Hautkr 1982; 57: 1733–1744

    PubMed  CAS  Google Scholar 

  14. Jorup-Rönström C, Britton S. Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection 1987; 15: 105–106

    Article  PubMed  Google Scholar 

  15. Bédane C. Dermo-hypodermites bactériennes aigües de l’adulte. Ann Dermatol Venereol 1997; 124: 57–60

    PubMed  Google Scholar 

  16. Jorup-Rönstrom C, Britton S, Gavlevik A, et al. The course, costs and complication of oral versus intravenous therapy of erysipelas. Infection 1984; 12: 390–394

    Article  PubMed  Google Scholar 

  17. Bernard P, Plantin P, Roger H, et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol 1992; 127: 155–159

    Article  PubMed  CAS  Google Scholar 

  18. Tan JS, Wischnow RM, Talan DA, et al. Treatment of hospitalized patients with complicated skin and skin structure infections: double blind randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicrob Agents Chemother 1993; 37: 1580–1586

    Article  PubMed  CAS  Google Scholar 

  19. Daly JS, Worthington MJ, Andrews RJ, et al. Randomized, double blind trial of cefonicid and nafcillin in the treatment of skin and skin structures infections. Antimicrob Agents Chemother 1990; 34: 654–656

    Article  PubMed  CAS  Google Scholar 

  20. Daniel R. Azithromycin, erythromycin and cloxacillin in the treatment of infections of the skin and asssociated soft tissues. J Int Med Res 1991; 19: 880–884

    Google Scholar 

  21. Kiani R. Double blind, double dummy comparison of azithromycin and cephalexin in the treatment of skin and skin structures infections. Eur J Clin Microbiol Infect Dis 1991; 10: 880–884

    Article  PubMed  CAS  Google Scholar 

  22. Heskel NS, Spieman N, Pichotta PJ, et al. Erythromycin versus cefadroxil in the treatment of skin infections. Int J Dermatol 1992; 31: 131–133

    Article  PubMed  CAS  Google Scholar 

  23. Nelder KH. Double blind randomized study of oral temafloxacin and cefadroxil in patients with mild to moderately severe bacterial skin infections. Am J Med 1991; 91: 111S–114S

    Article  Google Scholar 

  24. Gentry LO, Ramirez-Ronda CH, Rodriguez-Norida E, et al. Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections. Arch Intern Med 1989; 149: 2579–2583

    Article  PubMed  CAS  Google Scholar 

  25. Parrish LC, Jungkind D. Systemic antimicrobial therapy in skin and skin structures infections: comparison of temafloxacin and ciprofloxacin. Am J Med 1991; 91: 115S–119S

    Article  Google Scholar 

  26. Sjöblom AO, Eriksson B, Jorup-Rönstrom C, et al. Antibiotic prophylaxis in recurrent erysipelas. Infection 1993; 6: 390–394

    Article  Google Scholar 

  27. Bishara J, Golan-Cohen A, Robenshtok E, et al. Antibiotic use in patients with erysipelas: a retrospective study. Isr Med Assoc J 2001; 3: 722–724

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jean-Marie Bonnetblanc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bonnetblanc, JM., Bédane, C. Erysipelas. Am J Clin Dermatol 4, 157–163 (2003). https://doi.org/10.2165/00128071-200304030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200304030-00002

Keywords

Navigation